Type of organ
POPULARITY
70 episodes with biliary
13 episodes with biliary
6 episodes with biliary
6 episodes with biliary
4 episodes with biliary
3 episodes with biliary
11 episodes with biliary
6 episodes with biliary
6 episodes with biliary
3 episodes with biliary
6 episodes with biliary
5 episodes with biliary
4 episodes with biliary
3 episodes with biliary
2 episodes with biliary
5 episodes with biliary
12 episodes with biliary
6 episodes with biliary
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this episode of BARE It All Coffee Talk, Stephanie sits down with fellow board member Maria to explore the crucial role of advocacy in the biliary atresia journey. Whether you're a parent or a patient, effective advocacy can significantly impact your medical experience. Join us as we share our insights and experiences to support and guide others on their journeys. The incidence of biliary atresia is approximately one in 10,000 children, with the disease being more common in males and in Asian and African-American newborns. Biliary atresia is not an inherited disease and does not run in families. Biliary Atresia - UCSF transplant surgeons. If you or someone you know has experience with biliary atresia and is willing to share your journey publicly to support our initiative, don't hesitate to get in touch with us at contactus@bareinc.org. Let's amplify our voices and foster understanding together." Music by Magnetic_Trailer from Pixabay Connect with us: • Bare Inc. • Instagram • X - Twitter • Facebook • YouTube If your child is facing a life-saving liver transplant, please reach out to The Children's Organ Transplant Association or COTA. The COTA crew looks forward to learning more about your family's Biliary Atresia journey. COTA works with families to lessen the financial burden of a life-saving transplant and support is provided at absolutely no cost. Please call COTA today at 1-800-366-2682 or go to www.cota.org/getstarted to learn more about how they can help.
Hosts Roz and Josh are joined by Mack Morris, MD to discuss the key articles of the July issue of American Journal of Transplantation. [03:33] Biliary complications after adult-to-adult living-donor liver transplantation: An international multicenter study of 3633 cases https://doi.org/10.1016/j.ajt.2024.02.023 [13:07] The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation https://doi.org/10.1016/j.ajt.2024.02.008 [24:30] Should advanced perfusion be the standard of care for donation after circulatory death liver transplant? https://doi.org/10.1016/j.ajt.2024.03.021 [32:20] Immunosuppression Withdrawal in Living-donor Renal Transplant Recipients Following Induction with Anti-thymocyte Globulin and Rituximab: Results of a Prospective Clinical Trial https://doi.org/10.1016/j.ajt.2024.03.007 [40:30] Spatial multiomics of arterial regions from cardiac allograft vasculopathy rejected grafts reveal novel insights into the pathogenesis of chronic antibody-mediated rejection https://doi.org/10.1016/j.ajt.2024.01.004
Dr. Komanduri shares how he performs a successful ERCP, explains how patient anatomy dictates planning and explores why the double-wire technique – using Autotome™ Pro RX Cannulating Sphincterotome – is his preferred approach to biliary access.
In this episode, Dr. Alexander Vezeridis discusses advanced biliary interventions; covering stone removal procedures, technical success rates, and practical tips for using Spyglass cholangioscopy, laser lithotripsy, and endobiliary ablation. Dr. Vezeridis is an interventional radiologist, physician-scientist, and Assistant Professor of Radiology at Stanford. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Vezeridis highlights the importance of continuous learning, collaboration with other specialties, and shares his experiences and tips for optimizing patient outcomes. The doctors also touch on innovative approaches such as photodynamic therapy and the use of various tools in managing benign and malignant biliary diseases. --- TIMESTAMPS 00:00 - Introduction 03:25 - Setting Up Spyglass in Your Practice 10:50 - Patient Selection and Procedure Details 24:27 - Stone Fragmentation Techniques 27:35 - Success Rates and Patient Outcomes 35:06 - Endobiliary Ablation Techniques 47:35 - Laser Treatment for Biliary Obstructions 49:18 - Future Innovations --- RESOURCES BackTable VI Podcast Episode #146 - Spyglass Interventions with Dr. Jeffrey Chick and Dr. Ravi Srinivasa: https://www.backtable.com/shows/vi/podcasts/146/spyglass-interventions Spyglass - Boston Scientific: https://www.bostonscientific.com/en-US/medical-specialties/gastroenterology/advancements-cholangioscopy.html Percutaneous Gallstone Removal: Long-term Follow-up (Dr. Hovsepian Paper): https://www.jvir.org/article/S1051-0443(96)70766-2/pdf SIR's Percutaneous Cholangiopancreatoscopy (PCPS) registry: https://clinicaltrials.gov/study/NCT05210322 StarMed Endoscopic RFA Clinical Articles: https://www.starmedacademy.com/endoscopic-rfa-clinical-articles-elra Habib Endobiliary Ablation Catheter: https://www.bostonscientific.com/en-US/products/rf-ablation/habib-endohpb-bipolar-radiofrequency-catheter.html Interventional Radiology-Operated Choledochoscopic-Guided Radiofrequency Wire and Holmium Laser Ablations May Facilitate Treatment and Long-Term Patency of Benign Biliary Strictures: https://www.jvir.org/article/S1051-0443(18)31535-5/abstract Percutaneous Cholangioscope-Assisted Laser Incision of Severe Benign Hepaticojejunostomy Stenoses: https://pubmed.ncbi.nlm.nih.gov/35504434/ Percutaneous Endoluminal Benign Biliary Laser (PEBBL) (Clinical Trial): https://clinicaltrials.gov/study/NCT05567003
"When I got into medical school, the last thing in the world I wanted to be was a surgeon because I couldn't stand the sight of blood," said Dr. Mike Moser. Fast-forward to the present day, where Moser is now one of Saskatchewan's top kidney transplant surgeons, winning last year's Golden Scalpel Award for Pre-clerkship Education, the 2022 Logan Boulet Humanitarian of the Year Award, and numerous teaching awards. In this episode, the professor of general surgery at the University of Saskatchewan's College of Medicine takes us back to one pivotal day where everything changed, propelling forward his career in Hepato-pancreato-biliary (HPB) surgery and organ transplants Moser's research has pushed forward transplant science, and led to safer kidney biopsies. Along with interventional radiologist Dr. Chris Wall, Moser led the charge to bring NanoKnife technology to Saskatchewan. His team has now spent a decade using the tool to treat otherwise inoperable tumors. The NanoKnife relies on irreversible electroporation (IRE) — using electrical pulses to create tiny holes in tumor cells, causing them to die without harming surrounding structures. "I love making those little, elegant, tiny connections," said Moser, whose work focuses on destroying cancer cells, while preserving delicate tissue. Those two interests led to collaborations with various departments, including biomedical engineering, as well as chemistry, immunology, and pharmacology. Moser is most excited today to see IRE combined with immunotherapy, to enhance the body's immune response against cancer. "It's like a killed cell vaccine situation because we've got these dead, helpless cancer cells. They're still exposing their proteins," said Moser. Although the research is still in its early stages, Moser said the results so far show "great potential" in treating metastatic cancers. "One could actually treat the area where the tumor started without directly treating it,” he said.
Please visit answersincme.com/CKZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses patient-centered approaches to the diagnosis and treatment of biliary tract cancer. Upon completion of this activity, participants should be better able to: Recognize the importance of achieving an accurate diagnosis of biliary tract cancer (BTC); Outline strategies for reaching a diagnosis of BTC, including cholangiocarcinoma; and Describe patient-centered approaches to enhance outcomes for patients undergoing a diagnostic work-up for BTC.
The Latest Data on Zanidatamab for Biliary Tract Cancer: Shubham Pant, MD by i3 Health
Join us in this emotional episode of BARE It All, Coffee Talk, as we sit down with Aaron to hear his poignant journey with biliary atresia and transplant. Aaron bravely shares the challenges and triumphs of living with biliary atresia as an adult, offering a candid look into his life. The incidence of biliary atresia is approximately one in 10,000 children, with the disease being more common in males and in Asian and African-American newborns. Biliary atresia is not an inherited disease and does not run in families. Biliary Atresia - UCSF transplant surgeons. If you or someone you know has experience with biliary atresia and is willing to share your journey publicly to support our initiative, don't hesitate to get in touch with us at contactus@bareinc.org. Let's amplify our voices and foster understanding together." Music by Magnetic_Trailer from Pixabay Connect with us: • Bare Inc. • Instagram • X - Twitter • Facebook If your child is facing a life-saving liver transplant, please reach out to The Children's Organ Transplant Association or COTA. The COTA crew looks forward to learning more about your family's Biliary Atresia journey. COTA works with families to lessen the financial burden of a life-saving transplant and support is provided at absolutely no cost. Please call COTA today at 1-800-366-2682 or go to www.cota.org/getstarted to learn more about how they can help.
Get the latest data from ASCO 2024 about anti-HER2 therapies in biliary tract cancer. Credit available for this activity expires: 6/25/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001250?ecd=bdc_podcast_libsyn_mscpedu
We have a feeling that after this episode you're never going to look at your eyes the same way again. Yes, we said your eyes! What if we told you that they hold information regarding your physical and emotional health?Karen and Robyn are honored to welcome back Holistic Practitioner, Leadership and Wellness Coach Cristina Rodenbeck who is certified in Iridology, a non-invasive science and practice of eye analysis that can reveal your relative state of health, and an awareness tool that can support your health from a prevention-approach.Cristina is also certified in Bach Flower Remedies and Crystal Healing. She broke down the power of flowers within all areas of our lives in a recent Seeking Center episode – which we highly recommend listening to!In this episode though we're focusing on those two precious vehicles that allow us to see our world in all of its technicolor.Cristina gave Robyn the rundown of Iridology and she can't unsee the power and the blueprint in her very own eyes. We don't think you will either.Time to have your eyes wide open. MORE FROM CRISTINAVisit manipurawellness.com to find out more about all of Cristina's offeringsFollow Cristina @manipura_pets on Instagram.MORE ON IRIDOLOGYThe International Iridology Practitioners Association (IIPA) is a registered, non-profit organization, founded in 1982.If you want to explore iridology with a practitioner near you, here's IIPA's website with their registered iridologists.Find an Iridologist in your native land.Visit theseekingcenter.com for more from Robyn + Karen, plus mega inspo -- and the best wellness + spiritual practitioners, products and experiences on the planet! You can also follow Seeking Center on Instagram @theseekingcenter
Check out Nascentmc.com for medical writing assistance. visit learnAMAstyle.com for free downloads on medical writing and editing Adbry for Atopic Dermatitis The FDA has approved tralokinumab-ldrm (Adbry) as a 300 mg single-dose autoinjector for moderate-to-severe atopic dermatitis (AD) in adults, offering a more convenient delivery method. Adbry, which inhibits IL-13, was previously approved for adults in December 2021 and for pediatric patients aged 12 and older in December 2023. The approval was granted to LEO Pharma Inc. Augtyro for NTRK Tumors The FDA has approved repotrectinib (Augtyro) for treating solid tumors with NTRK gene fusions in patients aged 12 and older, based on Phase 1/2 trials showing significant response rates in both TKI-naïve and previously treated patients. The approval was granted to Bristol Myers Squibb, with additional clinical data required to confirm safety and efficacy. Donanemab for Alzheimer's FDA advisors unanimously recommended the approval of donanemab for Alzheimer's disease, emphasizing its efficacy in slowing early-stage disease and manageable risks. Donanemab, targeting amyloid plaques, offers potential advantages over Leqembi with monthly infusions. The FDA decision is expected soon. Iqirvo for Primary Biliary Cholangitis The FDA granted accelerated approval to elafibranor (Iqirvo) for primary biliary cholangitis (PBC) to be used with ursodeoxycholic acid or as monotherapy. Elafibranor targets PPAR-α and PPAR-δ, with Phase 2 trials showing significant biochemical responses. The approval was granted to GENFIT and Ipsen. Retevmo in Thyroid Cancer The FDA granted full approval to selpercatinib (Retevmo) for advanced or metastatic RET fusion–positive thyroid cancer in patients aged 2 years and older, based on the LIBRETTO-001 trial showing high response rates. The approval was granted to Eli Lilly and Company. OTC Continuous Glucose Monitors The FDA approved Abbott Laboratories' continuous glucose monitoring systems, Libre Rio and Lingo, for over-the-counter use. Libre Rio is for Type 2 diabetes patients not on insulin, while Lingo targets non-diabetic consumers for health improvement. These systems provide real-time glucose monitoring via a smartphone app. Check out Nascentmc.com for medical writing assistance.visit learnAMAstyle.com for free downloads on medical writing and editing
Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit. Launch Date: June 11, 2024 Release Date: June 11, 2024Expiration Date: May 31, 2025 Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis
Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit. Launch Date: June 11, 2024 Release Date: June 11, 2024Expiration Date: May 31, 2025 Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis
Join us in this episode of BARE It All, Coffee Talk, as we sit down with Jenna to delve into her son Alex's journey with biliary atresia and transplant. Jenna bravely shares the challenges and complications Alex faced post-transplant, offering listeners a glimpse into their daily lives and resilience. The incidence of biliary atresia is approximately one in 10,000 children, with the disease being more common in males and in Asian and African-American newborns. Biliary atresia is not an inherited disease and does not run in families. Biliary Atresia - UCSF transplant surgeons. If you or someone you know has experience with biliary atresia and are willing to share your journey publicly to support our initiative, please reach out to us at contactus@bareinc.org. Let's amplify our voices and foster understanding together." Music by Magnetic_Trailer from Pixabay Connect with us: • Bare Inc. • Instagram • X - Twitter • Facebook If your child is facing a life-saving liver transplant, please reach out to The Children's Organ Transplant Association or COTA. The COTA crew is looking forward to learning more about your family's Biliary Atresia journey. COTA works with families to lessen the financial burden of a life-saving transplant and support is provided at absolutely no cost. Please call COTA today at 1-800-366-2682 or go to www.cota.org/getstarted to learn more about how they can help.
In this episode, we review the high-yield topic of Cholelithiasis and biliary colic from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Staff at the NIHR Nottingham Clinical Research Facility talk about the UCAB trial. The facility worked with Swedish pharmaceutical Umecrime Cognition to study using a new molecule as a treatment for Primary Biliary Cholangitis (PBC) for patients with severe symptoms of fatigue and cognitive impairment. Quick takeaways - • one of only two UK locations for first stage drug trial • kept to tight, complex timelines • exceeded recruitment targets by building on existing relationships • patients praised care and treatment The NIHR Nottingham Clinical Research Facility (CRF) was one of just two centres worldwide – and the only UK facility – to conduct the first part of a clinical study. We were picked because of our expertise in liver disease. We hosted five patients on a purpose-built inpatient ward within the CRF, to confirm the correct dose of the molecule. During their seven-day stay, our team of research nurses and physicians assessed and cared for the patients around the clock. Nottingham CRF has 18 adult and five paediatric inpatient beds dedicated for research, alongside our dedicated outpatient and specialist clinics. In total, there is over 3,400m² of clinical space at our CRF. The PBC study was a randomised, double-blinded and placebo controlled two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of the new drug. There's more about it at https://nottinghamcrf.nihr.ac.uk/facilities/case-studies Follow us on Twitter: @NottmBRC Follow us on Instagram: @NottmHealthScience Follow us on Facebook: https://www.facebook.com/ResearchNottingham Watch a video explainer about clinical trials: https://youtu.be/SWS4FCSMWAQ Read more at https://www.nottinghamresearch.org/get-involved and https://www.nuh.nhs.uk/take-part-in-a-trial and https://www.nuh.nhs.uk/researchvolunteers Email us at getinvolved@nuh.nhs.uk
Have you ever heard of Biliary Dyskinesia? In this episode, I'll be opening up about my recent diagnosis of biliary hyperkinesia, discussing the symptoms I've experienced, and sharing the steps I'm taking to manage it. My hope is that by sharing my journey, it may offer support or guidance to anyone else who may be facing similar challenges or has a loved one going through a similar experience. Disclaimer: Please note that this podcast episode is based on my personal journey with Biliary Hyperkinesia. Always consult with a qualified healthcare professional for personalized medical advice and treatment options. In this episode you will learn: My Understanding Biliary Hyperkinesia: Learn about the uncommon disorder characterized by abnormal gallbladder contractions and its symptoms. Personal Experience: Hear a firsthand account of the journey with Biliary Hyperkinesia, from initial symptoms to diagnosis and ongoing treatment. Diagnostic Process: Gain insights into the diagnostic process, including medical tests like ultrasounds, bloodwork, colonoscopy, and the HIDA scan. Treatment Options: Discover the various treatment options available for managing Biliary Hyperkinesia. Coping Strategies and Support: Explore coping strategies, including being your own advocate, joining support groups, and prioritizing mental health, along with advice for listeners and loved ones. --- Support this podcast: https://podcasters.spotify.com/pod/show/thelatinamomlegacy/support
In this episode, Dr. Mark Lessne and Dr. John Martinie discuss the importance of multidisciplinary collaboration, patient-centered care, and the role of interventional radiology and surgery in treating benign and malignant biliary diseases. Dr. Lessne is an interventional radiologist at Charlotte Radiology and Dr. Martinie is a hepatobiliary surgeon at Carolinas Medical Center, both located in North Carolina. The doctors explore various scenarios including challenges in biliary decompression, the decision-making process behind choosing the right intervention, and the impact of such diseases on patient care plans and outcomes. Dr. Lessne and Dr. Martinie emphasize the importance of viewing interventional radiologists and gastroenterologists as physicians who not only perform procedures, but also provide comprehensive care and follow-up for their patients. Through their dialogue, it becomes clear that successful treatment of biliary diseases requires a combination of technical skill, thoughtful patient engagement, and collaborative practice among specialists. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES 00:00 - Introduction 02:19 - Multidisciplinary Approach to Patient Care 05:31 - Navigating the Complexities of Biliary Disease Workups 10:13 - Collaboration Between Hepatobiliary Surgery and Interventional Radiology 19:33 - Balancing Minimally Invasive Techniques with Surgical Options 30:29 - The Importance of Compassionate Consent and Patient-Centered Care 32:16 - Exploring Advanced Interventions and Team Discussions 36:31 - Considerations and Challenges in Biliary Stenting 45:46 - Role of Interventional Radiology in Patient Care 56:57 - Final Thoughts on Teamwork and Patient Care --- RESOURCES BackTable Ep. 203- Making Informed Consent an Informed Choice with the Interventional Initiative: https://www.backtable.com/shows/vi/podcasts/203/making-informed-consent-an-informed-choice-with-the-interventional-initiative
How familiar are you with emerging therapies for primary biliary cholangitis (PBC)? Credit available for this activity expires: 3/28/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000562?ecd=bdc_podcast_libsyn_mscpedu
In this episode of the BackTable Podcast, host Dr. Michael Barraza interviews guest Dr. Brian Holly about different surgical scenarios relating to biliary interventions. Dr. Holly is a practicing interventional radiologist and Assistant Professor of Radiology and Radiological Sciences at Johns Hopkins University. The doctors delve into various techniques including the usage of ultrasound, managing non-dilated and dilated systems, as well as handling specific clinical scenarios such as malignant obstructions, benign biliary strictures, and postoperative bile leaks. The podcast also briefly discusses the controversial topic of placing internal biliary stents and the challenges faced with managing biliary strictures and leaks. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES 00:00 - Introduction 01:53 - Discussion on IR Training at Johns Hopkins 04:09 - Overview of Biliary Interventions 08:31 - Challenges and Techniques in Biliary Access 19:28 - Approach to Non-Dilated Collecting System 28:07 - Dealing with Dilated Systems and Obstructions 32:56 - Biopsy Techniques for Malignant CBD Strictures 39:30 - Approach to Benign Biliary Strictures 41:48 - Use of Internal Stents in Biliary Procedures 44:51 - Managing Bleeding in Biliary Procedures --- RESOURCES The Hepaticojejunostomy Technique with Intra-Anastomotic Stent in Biliary Diseases and Its Evolution throughout the Years: A Technical Analysis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846744/ Percutaneous Transhepatic Cholangiography and Intraductal Radiofrequency Ablation Combined with Biliary Stent Placement for Malignant Biliary Obstruction: https://www.jvir.org/article/S1051-0443(15)00166-9/abstract
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.(00:32)Could you please provide a little information about your background? (02:09)Please give a brief overview of the new test panels. (05:35)Which patients should have this testing and when should it be performed? (09:49)What alternative test options are available, and how do those compare to our testing at Mayo Clinic Laboratories? (13:15)How are the results used in patient care?
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-vs-primary-sclerosing-cholangitis-do-you-know-the-difference/16642/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-the-phenotype-it-is-a-changin/16641/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-ibat-inhibition-and-beyond/16650/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-treatment-pipeline-for-primary-biliary-cholangitis-sorting-out-the-ppars/16649/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-for-primary-biliary-cholangitis-whos-on-first-whos-on-second/16647/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/goals-of-treatment-for-primary-biliary-cholangitis-a-balancing-act/16645/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-is-risky-business/16644/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 31-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-a-natural-history-lesson/16643/ Embark on a comprehensive CME journey through a multiepisodic series on Primary Biliary Cholangitis. From understanding evolving phenotypes to differentiating from Primary Sclerosing Cholangitis, each episode delves into crucial aspects. Real-life cases, like in "Risky Business," add a practical touch, while topics like "A Balancing Act" explore treatment goals. "Walk a Mile in My Shoes" offers a unique perspective, and discussions on "Long-Term Monitoring" and the treatment pipeline provide holistic insights, featuring distinguished faculty and enriching your knowledge base.
CME credits: 1.00 Valid until: 17-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/biliary-tract-and-pancreatic-cancer-her2-targeted-adcs-for-gastrointestinal-cancers/16560/ HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
In this episode, we review the high-yield topic of Secondary Biliary Cholangitis from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
A Christmas Day Miracle, by Dean and Talya Rotbart, is adapted from their 2020 biography of Margaret and Riyaz Adat, titled Improbable Lives: A Scot, A Tanzanian, and Their Canadian Love Story. A true-life, inspirational adult yuletide tale, A Christmas Day Miracle offers a universal message — regardless of readers' religious beliefs — about the wonder and power of life's unexpected blessings. Since the book was first published two years ago, it has become a perennial holiday favorite. We hope you enjoy it.
Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 1: Current Management Approaches for Patients with Advanced Biliary Tract Cancers (BTCs) — Lipika Goyal, MD, MPhil CME information and select publications
Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers | Faculty Presentation 2: Emerging Management Approaches for Patients with Advanced BTCs — Milind Javle, MD CME information and select publications
Featuring perspectives from Dr Lipika Goyal and Dr Milind Javle, including the following topics: Introduction (0:00) First-Line Systemic Treatment (17:25) Targeted Treatment (25:42) CME information and select publications
Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers.
Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers.
Dr Lipika Goyal from The Stanford Cancer Center and Dr Milind Javle from The University of Texas MD Anderson Cancer Center in Houston discuss targeted and immunotherapeutic approaches for biliary tract cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://researchtopractice.com/InsideTheIssue2023/BTC).
In this episode, Dr. Jerby repents for all the gallbladders that he took out that probably didn't need to be taken out. As a recovering surgeon and Integrative Functional GI Specialist, he now is doing everything he can to SAVE THOSE GALLBLADDERS! Don't have yours removed unless it's absolutely necessary. Listen to this podcast and find out more.Check out Dr. Jerby's Integrative Functional GI practice here.
Extrahepatic biliary cancer is a specific type of biliary cancer that occurs outside the liver. It is considered rare, quite serious and often symptomless until later stages. The average age at diagnosis is 72. Extrahepatic biliary cancer typically involves the bile ducts, which carry bile from the liver and gallbladder to the small intestine. It can also involve the gallbladder, which plays a role in the digestion of fats by storing, concentrating and releasing bile as needed. One of the main genetic factors that contribute to biliary cancer is the mutation of Kras, a gene that regulates cell growth and division. Mutated Kras can cause cells to grow uncontrollably and form tumors. Another important genetic factor is the mutation of p53, a gene that normally acts as a guardian of the genome and triggers cell death or repair when DNA damage occurs. Mutated p53 can impair this function and allow cells to survive and accumulate more mutations. “[...] the exact role of p53 in the development of extrahepatic biliary cancer remains elusive.” In a new editorial paper, researchers Munemasa Nagao, Kenta Mizukoshi, Shinnosuke Nakayama, Mio Namikawa, Yukiko Hiramatsu, Takahisa Maruno, Yuki Nakanishi, Tatsuaki Tsuruyama, Akihisa Fukuda, and Hiroshi Seno from Kyoto University Graduate School of Medicine discussed their recent study exploring the role of p53 in preventing the development of extrahepatic biliary cancer. On March 31, 2023, their editorial was published in Oncotarget, entitled, "p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras." Full blog - https://www.oncotarget.org/2023/11/02/p53s-protective-role-in-extrahepatic-biliary-precancerous-lesions/ Paper DOI - https://doi.org/10.18632/oncotarget.28380 Correspondence to - Akihisa Fukuda - fukuda26@kuhp.kyoto-u.ac.jp Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28380 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, BilIN, ICPN, biliary cancer, Kras, p53 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Did you know that 80% of children with biliary atresia who undergo a Kasai procedure will still require liver transplant at some point in their life? Dr. Bade, a pediatric gastroenterologist, joins medical students Tucker Oliver and Sarah Chappell to discuss evaluation and management of infants with biliary atresia. Specifically, they will: Discuss the presentation and diagnosis of biliary atresia Explain pathophysiology behind jaundice Discuss preoperative and postoperative recommendations for the Kasai procedure Review complications and outcomes of the Kasai procedure Share advice for navigating the diagnosis of biliary atresia with families Special thanks to Dr. Rebecca Yang and Dr. Jennifer Tucker for peer reviewing this episode. FREE CME Credit (requires free sign-up): Link Coming Soon! References: 1] P. J. Lupo et al., “Population-based birth defects data in the United States, 2010-2014: A focus on gastrointestinal defects.,” Birth Defects Res, vol. 109, no. 18, pp. 1504–1514, Nov. 2017, doi: 10.1002/bdr2.1145. [2] J. L. Hartley, M. Davenport, and D. A. Kelly, “Biliary atresia,” The Lancet, vol. 374, no. 9702, pp. 1704–1713, Nov. 2009, doi: 10.1016/S0140-6736(09)60946-6. [3] S. S. Sundaram, C. L. Mack, A. G. Feldman, and R. J. Sokol, “Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.,” Liver Transpl, vol. 23, no. 1, pp. 96–109, Jan. 2017, doi: 10.1002/lt.24640. [4] D. Volpert, F. White, M. J. Finegold, J. Molleston, M. DeBaun, and D. H. Perlmutter, “Outcome of Early Hepatic Portoenterostomy for Biliary Atresia,” J Pediatr Gastroenterol Nutr, vol. 32, no. 3, pp. 265–269, Mar. 2001, doi: 10.1097/00005176-200103000-00006. [5] R. Fawaz et al., “Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.,” J Pediatr Gastroenterol Nutr, vol. 64, no. 1, pp. 154–168, Jan. 2017, doi: 10.1097/MPG.0000000000001334. [6] P. H. Y. Chung et al., “Life long follow up and management strategies of patients living with native livers after Kasai portoenterostomy.,” Sci Rep, vol. 11, no. 1, p. 11207, May 2021, doi: 10.1038/s41598-021-90860-w. [7] E. H. Gad, Y. Kamel, T. A.-H. Salem, M. A.-H. Ali, and A. N. Sallam, “Short- and long-term outcomes after Kasai operation for type III biliary atresia: Twenty years of experience in a single tertiary Egyptian center-A retrospective cohort study.,” Ann Med Surg (Lond), vol. 62, pp. 302–314, Feb. 2021, doi: 10.1016/j.amsu.2021.01.052. [8] A. M. Calinescu et al., “Cholangitis Definition and Treatment after Kasai Hepatoportoenterostomy for Biliary Atresia: A Delphi Process and International Expert Panel.,” J Clin Med, vol. 11, no. 3, Jan. 2022, doi: 10.3390/jcm11030494. [9] S. Kiriyama et al., “Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos),” J Hepatobiliary Pancreat Sci, vol. 25, no. 1, pp. 17–30, Jan. 2018, doi: 10.1002/jhbp.512. [10] K. Decharun, C. M. Leys, K. W. West, and S. M. E. Finnell, “Prophylactic Antibiotics for Prevention of Cholangitis in Patients With Biliary Atresia Status Post-Kasai Portoenterostomy,” Clin Pediatr (Phila), vol. 55, no. 1, pp. 66–72, Jan. 2016, doi: 10.1177/0009922815594760. [11] E. Jung, W.-H. Park, and S.-O. Choi, “Late complications and current status of long-term survivals over 10 years after Kasai portoenterostomy.,” J Korean Surg Soc, vol. 81, no. 4, pp. 271–5, Oct. 2011, doi: 10.4174/jkss.2011.81.4.271. [12] S. S. Sundaram et al., “Health related quality of life in patients with biliary atresia surviving with their native liver.,” J Pediatr, vol. 163, no. 4, pp. 1052–7.e2, Oct. 2013, doi: 10.1016/j.jpeds.2013.04.037. [13] B. L. Shneider et al., “Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia.,” Pediatrics, vol. 130, no. 3, pp. e607-14, Sep. 2012, doi: 10.1542/peds.2011-1423. [14] J. P. Molleston and B. L. Shneider, “Preventing variceal bleeding in infants and children: is less more?,” Gastroenterology, vol. 145, no. 4, pp. 719–22, Oct. 2013, doi: 10.1053/j.gastro.2013.08.026. [15] G. Grisotti and R. A. Cowles, “Complications in pediatric hepatobiliary surgery,” Semin Pediatr Surg, vol. 25, no. 6, pp. 388–394, Dec. 2016, doi: 10.1053/j.sempedsurg.2016.10.004. [16] F. R. Sinatra, “Consultation with the Specialist: Liver Transplantation for Biliary Atresia,” Pediatr Rev, vol. 22, no. 5, pp. 166–168, May 2001, doi: 10.1542/pir.22-5-166. [17] I. Sriram and D. Nicklas, “Biliary Atresia,” Pediatr Rev, vol. 43, no. 11, pp. 659–661, Nov. 2022, doi: 10.1542/pir.2021-005287. [18] L. H. Rodijk et al., “Parental wellbeing after diagnosing a child with biliary atresia: A prospective cohort study.,” J Pediatr Surg, vol. 57, no. 4, pp. 649–654, Apr. 2022, doi: 10.1016/j.jpedsurg.2021.05.026. [19] A. Sanchez-Valle, N. Kassira, V. C. Varela, S. C. Radu, C. Paidas, and R. S. Kirby, “Biliary Atresia: Epidemiology, Genetics, Clinical Update, and Public Health Perspective.,” Adv Pediatr, vol. 64, no. 1, pp. 285–305, Aug. 2017, doi: 10.1016/j.yapd.2017.03.012.
Expert Approach to Hereditary Gastrointestinal Cancers presented by CGA-IGC
This episode is hosted by Julie Yang, MD, a gastroenterologist at the Icann School of Medicine at Mount Sinai, New York, USA and features Toni T. Seppälä, M.D., PhD, a GI surgeon and Professor of Cancer Research at Tampere University, Helsinki, Finland. They discuss the results from a retrospective analysis published this year, “Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry," which can be found here. Read our blog post "Insights gained from the largest cohort of patients with pancreaticobiliary cancer and Lynch Syndrome" here
If you experience high cholesterol or headaches, among other symptoms, while fasting—you may have bile sludge. Find out why bile sludge can occur during a prolonged fast. DATA: https://bit.ly/3M4w58t Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/
© 2020-2025 Ivy Podcast Discovery LLC
